No serious health effects linked to mRNA COVID-19 vaccines

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.

The study published September 2 in JAMA reports the first comprehensive findings of the Vaccine Safety Datalink (VSD), which studies patient records for 12 million people in 5 Kaiser Permanente service regions along with HealthPartners in Minneapolis, the Marshfield Clinic in Wisconsin, and Denver Health. The work is supported by the Centers for Disease Control and Prevention (CDC).

"These results from our safety surveillance are reassuring," said lead author Nicola Klein, MD, PhD, director of the Kaiser Permanente Vaccine Study Center and principal investigator of the Vaccine Safety Datalink's COVID-19 rapid cycle analysis.

"The world is relying on safe and effective vaccines to bring an end to the COVID-19 pandemic. The Vaccine Safety Datalink is ideally suited to carry out this important surveillance and we will continue to monitor the safety of all vaccines that protect against COVID-19," added Dr. Klein, who is also a senior research scientist with the Kaiser Permanente Division of Research.

The study reported findings from mid-December 2020 through June 26, 2021. Some of the early findings had been summarized previously and reported at public meetings of the CDC’s Advisory Committee on Immunization Practices, though the JAMA article is the VSD’s first comprehensive report of its safety surveillance of the Pfizer and Moderna mRNA vaccines.

The analyses compared specific health events among all COVID-19 mRNA-vaccinated people during the first 3 weeks after inoculation with health events among similar types of patients during the 3 to 6 weeks after mRNA vaccination. The total number of people evaluated was 6.2 million for the first dose of either mRNA vaccine and 5.7 million for the second dose.

The design is meant to compare patients who are as similar to one another as possible to reduce the number of factors that could complicate the results. The authors added a comparison group of unvaccinated patients in a supplemental analysis.

The researchers examined 23 potential health effects, chosen because they had been included in previous vaccine studies, were of particular concern as an effect of COVID-19, were noted during the COVID-19 clinical trials, or were added after public health officials reported increased cases among vaccinated people. Outcomes tracked included neurological disorders such as encephalitis and myelitis, seizures, and Guillain-Barré syndrome; cardiovascular problems such as acute myocardial infarction, stroke, and pulmonary embolism; and others such as Bell’s palsy, appendicitis, anaphylaxis, and multisystem inflammatory syndrome.

Patient medical records were searched electronically and analysts carried out chart reviews of specific health outcomes to verify the medical problem and to assess whether it started before or after vaccination.

Vaccine Safety Datalink researchers then applied statistical analysis to determine whether the number of incidents was above a certain threshold, or “signal.” They concluded that none of the target health outcomes reached the signal, though for some outcomes the findings were less precise because of small numbers of cases. The authors said VSD safety surveillance is ongoing, which will increase the precision of estimates for those outcomes.

The study authors highlighted their findings about cases of confirmed myocarditis and pericarditis among young individuals, as that has become an outcome of concern. The VSD study identified 34 such cases in patients 12 to 39 years old; 85% of them were male and 82% hospitalized (for a median of 1 day), and nearly all recovered by the time the chart review took place. The authors calculated that among patients 12 to 39 years old, there is a risk of 6.3 additional myocarditis cases per million doses during the first week after vaccination. Other research has calculated a significantly higher risk of myocarditis from COVID-19 than from the vaccine.

"The results of this study are a great example of how seriously CDC takes vaccine safety, and how thorough and transparent we are in our safety monitoring efforts," said Tom Shimabukuro, MD, leading vaccine safety for the COVID-19 response and the deputy director of CDC’s Immunization Safety Office. "It is our top priority to do the science and communicate quickly and clearly with healthcare providers and the public, as COVID-19 vaccines continue to undergo the most intensive safety monitoring in U.S. history. Getting vaccinated remains the best way to protect yourself and your loved ones against a virus that has taken millions of lives."

The VSD’s rapid-cycle analysis for the mRNA COVID-19 vaccines will continue tracking newly vaccinated patients for at least 2 years. The VSD, established in 1990 and led by the CDC, Kaiser Permanente, and other health care systems, is the nation’s premier active surveillance system for vaccine safety.

Klein NP, Lewis N, Goddard K, et al.
Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
JAMA. Published online September 03, 2021. doi: 10.1001/jama.2021.15072

Most Popular Now

Novartis provides more than USD 25 million in medi…

Novartis announced that it condemns the war in Ukraine: "The continued acts of unprovoked violence are harming innocent people, and this defies our mission to improve hum...

Findings open way for personalised MS treatment

Currently available therapies to treat multiple sclerosis (MS) lack precision and can lead to serious side effects. Researchers at Karolinska Institutet in Sweden have no...

Pfizer and Biohaven's VYDURA® (rimegepant) granted…

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorizatio...

Pfizer shares top-line results from Phase 2/3 EPIC…

Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating...

A smarter way to develop new drugs

Pharmaceutical companies are using artificial intelligence to streamline the process of discovering new medicines. Machine-learning models can propose new molecules that ...

Cognitive impairment from severe COVID-19 equivale…

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team o...

A new toolkit to engineer safe and efficient thera…

Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cell...

SK bioscience and GSK's adjuvanted COVID-19 vaccin…

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s...

Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partners...

Asthma drug can block crucial SARS-CoV-2 protein

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, ac...

Investigational COVID mucosal vaccine protects aga…

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spr...

Using AI to analyze large amounts of biological da…

Researchers at the University of Missouri are applying a form of artificial intelligence (AI) - previously used to analyze how National Basketball Association (NBA) playe...